IVI and Bloom Public Health Group partner to advance vaccine equity and strengthen health security in Africa

The International Vaccine Institute (IVI) and Bloom Public Health Group announced a new partnership to accelerate vaccine equity and strengthen health security across Africa. A memorandum of understanding formalizes the collaboration, leveraging IVI’s global scientific expertise and Bloom’s on-the-ground knowledge to build a more resilient African vaccine ecosystem.

The partnership will drive joint initiatives in critical areas, including vaccine research and development, regulatory system strengthening, local manufacturing capacity, and public health implementation.

“This partnership is a significant step toward our shared vision of a world where safe and effective vaccines are accessible to everyone,” said Prof. Nicaise Ndembi, Deputy Director General and Africa Regional Director of IVI. “By uniting IVI’s end-to-end vaccine development capabilities with Bloom’s deep local networks, we can co-create sustainable systems that directly improve health outcomes and health security for African nations.”

Prof. Chimezie Anyakora, CEO of Bloom Public Health Group, emphasized the partnership’s role in advancing African health sovereignty. “We are excited to join forces with IVI to empower African-led health solutions,” he said. “This collaboration is a direct catalyst toward the continent’s goal of manufacturing 60% of its required vaccines locally by 2040. By combining our strengths, we will not only ensure more equitable access to vaccines but also build the foundational capacity for Africa to control its own health destiny.”

The IVI-Bloom partnership aims to create stronger, more self-reliant health systems across Africa, better equipped to meet current public health needs and respond to future emergencies.